GASTROENTEROLOGY

Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, and State of the Finances

Feb 6, 2018 by in GASTROENTEROLOGY Comments Off on Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, and State of the Finances

1. Expression system 2. Manufacturing process 3. Assessment of physiochemical properties 4. Functional activities 5. Receptor binding and immunochemical properties 6. Measurement of impurities 7. Stability under multiple stress conditions…

read more

Therapeutic Drug Monitoring of Biologic Agents

Feb 6, 2018 by in GASTROENTEROLOGY Comments Off on Therapeutic Drug Monitoring of Biologic Agents

Assay type Advantages Disadvantages Commercial example in United States ELIS A •  Ease of administration • Generally low cost •  False positives •  Interference in measuring antibodies in the presence of…

read more

Novel Agents in Inflammatory Bowel Disease

Feb 6, 2018 by in GASTROENTEROLOGY Comments Off on Novel Agents in Inflammatory Bowel Disease

Crohn’s disease Mechanism Ulcerative colitis Vedoli zumab (approved) Anti-integrin Vedolizumab (approved) Etrolizumab (phase III) Etrolizumab (phase III) PF-00547659 (phase II) PF-00547659 (phase II) Ozanimod (phase II) Sphingosine-1-phosphate inhibitor Ozanimod (phase…

read more
Premium Wordpress Themes by UFO Themes